Harmony Biosciences Q1 revenue rises 20% to $184.7 million; 2025 guidance reaffirmed
Harmony Biosciences reported first-quarter 2025 results, with WAKIX net product revenue of $184.7 million, up 20% from $154.6 million a year earlier, and GAAP net income of $45.6 million, or $0.78 per diluted share, versus $0.67 a year earlier. The company reaffirmed its full-year 2025 net product revenue guidance of $820 million to $860 million, and the filing also includes an investor presentation posted to its website.
Key points
- Q1 2025 net product revenue $184.7 million, up 20% from $154.6 million in Q1 2024
- GAAP net income $45.6 million, or $0.78 per diluted share, versus $0.67 in Q1 2024
- Full-year 2025 net product revenue guidance of $820 million to $860 million reaffirmed, not changed
- Total operating expenses rose 29% to $96.5 million, led by a 56% rise in R&D to $34.5 million; cash and investments were $610.2 million at March 31, 2025
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.